Mexico: Pharmaceutical companies in Mexico capitalise on market conditions
2017/04/11
The Mexican pharmaceutical industry has potential for the deployment of research and improvment(R&D) capital. Since 2010 the strategy of the Federal Commission for the Protection from Sanitary Risk (Comisión Federal para la Protección contra Riesgos Sanitarios, Cofepris), the regulatory body governing the sector, has enabled faster licensing of new products and allowed Mexico to become one of the majority developed markets for generic drugs in the world.
“Cofepris has implemented new reforms, undergone transition and has excelled in setting high standards for the pharmaceutical sector,” Gurulinga Konanur, CEO of Hetero Drugs, told OBG. “Entry barriers are high and regulations are thorough, meaning Mexico is on par with developed markets and above the standards of other Latin American nations.” The pharmaceutical, veterinary and medical devices industry accounts for 4.5% of GDP, and there are an estimated 300 drug companies in the country, of which 70% have manufacturing facilities.
CLINICAL TRIALS: According to Rafael Gual Cosío, director-general of the National Chamber of the Pharmaceutical Industry, his organisation’s 200 members had investment plans totalling over MXN40bn ($2.4bn) as of February 2017. One area of particular interest is clinical research. In June 2016 US drug giant Pfizer announced it would invest MXN280m ($16.9m) in clinical research in Mexico. In March of that year Portuguese arrangement research firm Eurotrials announced it would open an office in Mexico, citing the government’s efforts to make the country additional attractive to R&D investment as a driver of the decision. With an opportunity to corner the market for clinical trials on Latin American patients, the industry is expected to triple in the coming years to $500m, according to the Mexican Association of Pharmaceutical Research Industries.
BIOTECH: In March 2015 new rules governing biosimilar pharmaceuticals, a biologic medicine that is similar to an extra drug that has by presently been authorised for use, came into result in Mexico. It clarified a 2013 regulation that led to fears that some biosimilar drugs may be removed from pharmacy shelves. The new legislation requires that Cofepris decide, on a case-by-case basis, which tests are needed to prove biosimilarity. The clarification bodes well for investment in production and research of biosimilars in Mexico. In July 2016 Mexican pharmaceutical manufacturer Neolpharma announced it would invest $20m to upgrade its factory and produce biosimilars in 2017. “New research in the field of bio-mechanics continues to produce innovation in product design,” Bernd Schreiber, director-general of Festo, a local industrial control and automation company, told OBG. “Particularly, research on living organisms is changing the way we think of mechanical systems and their application in various industries.”
GOVERNMENT SUPPORT: Perhaps the biggest opportunity for Mexico is in the development of new generic products, given the high penetration of generic drugs in the country. “The objective for pharmaceutical companies is to keep costs low, both for production and for sale. The majority appropriate strategy for Mexico is to develop highly innovative drugs in high-tech laboratories; however, there has been a lack of government incentives to develop these products,” Victor Sanchez, CEO of Disur, a pharmaceutical distributor, told OBG. Due to budget cuts at the National Council for Science and Technology, next funding will be devoted to companies further along the technology development chain, and generic pharmaceutical products fall into that category. The country’s skilled labour force is as well attractive for companies looking to develop new products. “Although the price of raw materials is equal around the globe, the price of researching and developing products, inclunding the cost of labour, is much lower in Mexico than in the US or Europe,” Vicente Saro, director-general of Chinoin, a pharmaceutical firm, told OBG. “This presents a natural attraction for large pharmaceutical companies that are interested in these activities for the same quality but at a lower cost.”
- Related Articles
-
Netanyahu to pioneer new diplomatic grounds in Latin America
2017/09/13 Defying doomsayers concerned about Israel losing diplomatic clout, Benjamin Netanyahu is headed to Bogota, Argentina, and Mexico -- part other Latin American nations. Prime Minister Benjamin Netanyahu is scheduled to depart for Latin America and the US on Sunday evening, marking the fifth time in some 15 months he will embark on ground-breaking trips to nations at no time before visited by a sitting Israeli prime minister. -
UNWTO: International tourism – strongest half-year results since 2010
2017/09/09 Destinations worldwide welcomed 598 million international tourists in the initial six months of 2017, some 36 million additional than in the same period of 2016. At 6%, increase was well above the trend of recent years, making the current January-June period the strongest half-year since 2010. Visitor numbers reported by destinations around the world reflect strong request for international travel in the initial half of 2017, according to the new UNWTO World Tourism Barometer. Worldwide, international tourist arrivals (overnight visitors) increased by 6% compared to the same six-month period last year, well above the sustained and consistent trend of 4% or higher increase since 2010. This represents the strongest half-year in seven years. -
Mexico expels North Korean ambassador over nuclear tests
2017/09/08 The Mexican government on Thursday said it had declared the North Korean ambassador to Mexico persona non grata in turmoil at the country’s nuclear tests, an unusually firm step that moved it closely into line with Washington. In a statement, the government said it had given Kim Hyong Gil 72 hours to leave Mexico in order to express its “absolute rejection” of North Korea’s recent nuclear activity, describing it as a grave threat to the region and the world. -
U.S. trade rep says in NAFTA talks he keeps Trump's views in mind
2017/09/06 U.S. Trade Representative Robert Lighthizer said on Tuesday that he and President Donald Trump are in full agreement on the NAFTA trade pact’s problems and believes that Trump will support any final modernization transaction that he negotiates. Next closing out five days of talks in Mexico City, Lighthizer said that he considers Trump’s views in each decision he makes in negotiations over the North American Free Trade Agreement. -
China Invites 5 Countries As Guests For BRICS Summit
2017/09/04 China has invited Egypt, Guinea, Tajikistan, Mexico and Thailand as guest nations for the upcoming BRICS summit but clarified that the invitation is not an attempt to expand the group under its 'BRICS Plus'border. China will host the BRICS summit in Xiamen city from September 3 to 5 in which leaders of the five nations will participate, inclunding Prime Minister Narendra Modi. "We need to have some further explanation about the BRICS Plus to help people better understand the rationale of this idea," Chinese Foreign Minister Wang Yi said in Beijing, addressing the media about BRICS (Brazil, Russia, India, China and South Africa) summit.
-
- Mexico News
-
- ISRAEL: Netanyahu to pioneer new diplomatic grounds in Latin America
- AFGHANISTAN: UNWTO: International tourism – strongest half-year results since 2010
- NORTH KOREA: Mexico expels North Korean ambassador over nuclear tests
- CANADA: U.S. trade rep says in NAFTA talks he keeps Trump's views in mind
- CHINA: China Invites 5 Countries As Guests For BRICS Summit
- CANADA: Why Mexico, Canada can discount Trump’s remarks on NAFTA?
- Trending Articles
-
- CHINA: Life after Rosneft deal: CEFC ambitions face debt, regulatory hurdles
- SOUTH AFRICA: KPMG's South Africa bosses purged over Gupta scandal
- TANZANIA: Critic of Tanzania's Magufuli moved to Kenya for treatment of gunshot wounds
- CHINA: Former Fed official Fisher: China could be the key to solving the North Korea crisis
- FRANCE: Aluminium-Lithium Alloys Fight Back
- CHINA: BRICS countries considering own cryptocurrency as settlement mechanism